After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.
Source link
About The Author
After its COVID success, Moderna endured years of falling vaccine sales, a plummeting stock price and attacks on its science. Now, its melanoma vaccine data notched a much-needed win for the company.